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a b s t r a c t
Aim: We wanted to investigate third-trimester HbA1c as a predictor of diabetes after gesta-
tional diabetes mellitus (GDM).
Methods: Women with GDM were followed up prospectively for ﬁve years from pregnancy to
detect the development of diabetes. The ability of HbA1c to predict diabetes was evaluated
with receiver-operating characteristic (ROC) curves and logistic regression analysis.
Results: By ﬁve years, 73 of 196 women had been diagnosed with diabetes. An optimal cut-off
point for HbA1c of 36mmol/mol (5.4%) could predict diabetes with 45% sensitivity and 92%
speciﬁcity. For HbA1c ≥39mmol/mol (≥5.7%), sensitivity, speciﬁcity, and positive predictive
value were 30%, 97%, and 91%, respectively. In logistic regression analysis, adjusting for
the diagnostic glucose concentration during pregnancy, HbA1c levels in the upper quartile
(≥36mmol/mol) were associated with a 5.5-fold increased risk of diabetes.
Conclusion: Third-trimester HbA1c levels in the pre-diabetes range revealed women with
post-partum diabetes with high speciﬁcity and high positive predictive value. HbA1c test-
ing could be used as a strategy to select high-risk women for lifestyle interventions aimed
at prevention of diabetes starting during pregnancy. The results should encourage further
validation in other populations using new diagnostic criteria for GDM.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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1. Introduction
Post-partum follow-up of pregnancies with gestational dia-
betes mellitus (GDM) is important, as these women have a
several-fold increased risk of progression to type-2 diabetes
after delivery [1]. It has been shown that there is a beneﬁcial
effect of lifestyle intervention on the 10-year risk of diabetes
in women with a history of GDM [2]. However, the uptake of
post-partum screening after GDM is suboptimal, and women
fail to attend the post-partum visit, even in a research setting
[3–6]. An easy way of identifying those who are at highest risk
of developing diabetes after pregnancy is needed, so that mid-
wives and physicians can pay more attention to these women
and start intervention already in pregnancy when the women
are more likely to be highly motivated.
HbA1c analysis was recently endorsed as a screening test
for unrecognized diabetes in early pregnancy [7–9], but it has
not yet been advocated as a diagnostic test for GDM. There is
some interest in ﬁnding an HbA1c threshold at other stages
of pregnancy that could even be used for intervention dur-
ing pregnancy. HbA1c as a diagnostic test has advantages for
both patients and physicians. It can be performed without
fasting, and is more reproducible and less cumbersome than
an oral glucose tolerance test (OGTT) [10]. However, we and
others have found a low sensitivity of HbA1c testing relative
to an OGTT in diagnosing diabetes and pre-diabetes inwomen
who have previously had GDM [5,11–16]. Very few studies have
evaluated the clinical usefulness of third-trimester HbA1c lev-
els as a way of predicting the development of post-partum
diabetes [17–21]. In a previous study from our geographical
area, we found that 30% of the women with GDM in the study
cohort had already developeddiabetes ﬁve years after delivery,
and that HbA1c levels≥38mmol/mol (≥5.6%) at the diagnostic
OGTT during pregnancy, corresponding to the upper quartile,
were associated with a four-fold increased risk of developing
diabetes [17]. The aim of the present study was to investigate
the HbA1c level measured close to the twenty-eighth week of
pregnancy as a predictor of diabetes development up to ﬁve
years after pregnancy.
2. Material and methods
2.1. Participants
The prospective Mamma Study followed women in southern
Sweden who gave birth during the years 2003–2005, for up
to 5 years from delivery, to detect the development of post-
partum diabetes. A detailed description of the study design
has already been reported [6]. Brieﬂy, pregnant women, rep-
resenting different glucose categories according to an OGTT,
were invited to take part in the study. A 75-g OGTT was offered
to all women in the twenty-eighth week of gestation, exclud-
ing thosewhowere diagnosedwith diabetes before pregnancy.
The diagnostic criteria for GDM were a slight modiﬁcation of
the European Association for the Study of Diabetes (EASD)
criteria, deﬁning GDM as a 2-h capillary blood glucose concen-
tration of ≥9.0mmol/l [22], corresponding to a plasma glucose
concentration of ≥10.0mmol/l [23]. Based on this deﬁnition,
391 women were recruited. HbA1c was measured within two
weeks of the diagnosis of GDM. Participants were followed
for the development of diabetes by means of an OGTT at 1–2
years and at 5 years after pregnancy—or until the diagno-
sis of diabetes. Based on the stated country of origin of at
least three grandparents, women were grouped according to
whether they were of European or non-European origin. Diag-
nostic criteria during follow-up were those proposed by the
World Health Organization (WHO) 1999 [24]. According to the
results of the OGTT, women were classiﬁed as having nor-
mal glucose tolerance (NGT), impaired fasting glucose (IFG),
impaired glucose tolerance (IGT), or diabetes. Participants gave
written informed consent and the Ethics Committee of Lund
University approved the study (LU 259-00), which was per-
formed according to the Declaration of Helsinki.
2.2. Metabolic measurements
TheHemoCueGlucose 201+ system (HemoCueAB,Ängelholm,
Sweden) was used for immediate measurement of plasma
glucose concentrations (mmol/l). HbA1c was measured with
ion-exchange chromatography procedures (Variant II from
BioRad; Tosoh G7 from Tosoh Bioscience; and in-house Mono
S) with results that were traceable to the Mono S procedure at
the Swedish Reference Laboratory. Values given in % (Mono S)
were converted to NGSP units (%) and IFCC units (mmol/mol)
using the regression equations developed by the IFCCWorking
Group [25].
2.3. Statistical analysis
HbA1c values are given as mmol/mol with % NGSP units
in parentheses or brackets. Continuous variables are sum-
marized by means and standard deviations (SDs) or 95%
conﬁdence intervals (CIs). Differences between group means
were compared with analysis of variance (ANOVA). Logistic
regression analysis was used to calculate the odds ratios (ORs)
and 95% CI for 5-year diabetes risk in different quartiles of
HbA1c levels. A receiver-operating characteristic (ROC) curve
was plotted to evaluate the diagnostic performance of HbA1c
in diabetes prediction. Sensitivity, speciﬁcity, positive predic-
tive value (PPV), negative predictive value (NPV), and the area
under the curve (AUC) were calculated. Threshold for discrim-
ination was calculated with the Youden index [26]. IBM SPSS
Statistics 22.0 for Windows (IBM Corporation, Armonk, NY,
USA) was used for analysis. Two-sided p-values of less than
0.05 were considered to be statistically signiﬁcant.
3. Results
Of the 391 women who agreed to participate prospectively, 5-
year data were available for 196 of them. Among these, 73%
were of European origin (mostly Swedish) and 27% were of
non-European origin (with Arab and Asian origin being the
largest groups).
Mean values for maternal age, diagnostic 2-h plasma glu-
cose concentration, and HbA1c level during pregnancy in
participantswere 33.3 (SD 4.9) years, 11.1 (1.7)mmol/l, and 33.1
(7.1)mmol/mol [5.2% (1.1%)], respectively. The correspond-
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Table 1 – Diagnostic indices of various HbA1c thresholds to predict diabetes ﬁve years after pregnancy using normal
glucose tolerance at 5-year follow-up as a reference.
HbA1c cut-off na Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
≥48mmol/mol (≥6.5%) 10 13.7 100.0 100.0 48.8
≥45mmol/mol (≥6.3%) 12 16.4 100.0 100.0 49.6
≥42mmol/mol (≥6.0%) 15 19.2 98.3 93.3 50.0
≥39mmol/mol (≥5.7%) 24 30.1 96.7 91.2 53.2
≥36mmol/mol (≥5.4%) 38 45.2 91.7 86.8 57.8
≥32mmol/mol (≥5.1%) 75 71.2 61.7 69.3 63.8
PPV, positive predictive value; NPV, negative predictive value.
a Number of women who reached the threshold value.
Fig. 1 – Predictive accuracy of HbA1c in detecting diabetes
ﬁve years after gestational diabetes, using women with
normal glucose tolerance as a reference. Various cut-off
points are shown.
ing ﬁgures for non-participants were 32.4 (5.8) years, 11.0
(1.1)mmol/l, and 32.7 (5.8)mmol/mol [5.1% (0.9%)], and the dif-
ferences compared to participants were not signiﬁcant. After
ﬁve years, 73 women had been diagnosed with diabetes: 14
before the ﬁrst follow-up, 25 at the ﬁrst (1- to 2-year) follow-up,
13 between the ﬁrst follow-up and the ﬁnal (5-year) follow-up,
and 21 at the ﬁnal follow-up. Of the remaining 123womenwho
participated in the 5-year follow-up (out of a total of 144), 60
were classiﬁed as having NGT and 63 were classiﬁed as having
IFG/IGT (pre-diabetes).
The mean HbA1c level during pregnancy in women who
had developed diabetes after 5 years was 36.7 (95% CI:
34.5–38.8)mmol/mol [5.5% (5.3–5.7%)], as compared to 31.4
(30.4–32.4)mmol/mol [5.0% (4.9–5.1%)] in women with pre-
diabetes and 30.6 (29.5–31.7)mmol/mol [4.9% (4.8–5.1%)] in
women with NGT at 5 years (p<0.0001).
Using NGT at 5-year follow-up as a reference, an ROC curve
was constructed to evaluate HbA1c as a predictor of dia-
betes up to ﬁve years after pregnancy (Fig. 1). The ability of
the ROC curve to predict diabetes was fair (AUC=0.720, 95%
CI: 0.634–0.806, p<0.0001), with an optimal cut-off point of
36mmol/mol (5.4%), resulting in a sensitivity of 45% and a

























Fig. 2 – HbA1c levels plotted against the diagnostic 2-h
glucose concentration during pregnancy for 196 women
with gestational diabetes. Various diagnostic cut-off levels
are shown, and the diagnoses at the 5-year follow-up are
indicated by symbols.
speciﬁcity of 92%. Table 1 shows the sensitivity, speciﬁcity,
PPV, and NPV for various cut-offs. Overall, HbA1c showed high
speciﬁcity and PPV, but the sensitivity was low. The predic-
tion did not improve by using both NGT and IFG/IGT at 5-year
follow-up as a reference (AUC=0.710, 95% CI: 0.630–0.791,
p<0.0001). Similar results were obtained when we included
women of Nordic origin only (diabetes, n=23 vs. NGT, n=44;
AUC=0.734, 95% CI: 0.588–0.879, p=0.002).
In Fig. 2, HbA1c levels are plotted against the diagnostic 2-
h capillary plasma glucose concentrations during pregnancy
for the whole study group. After ﬁve years, all ten women
with HbA1c levels ≥48mmol/mol (≥6.5%) had been diagnosed
with diabetes, six women before the ﬁrst follow-up (HbA1c
51–70mmol/mol [6.8–8.6%]), one woman at the ﬁrst follow-up
(HbA1c 57mmol/mol [7.4%]), and three women at the ﬁve-
year follow-up (HbA1c 50–55mmol/mol [6.7–7.2%]). Similarly,
in 13 women with HbA1c levels ≥45mmol/mol (≥6.3%) all but
1 woman (IGT) had been diagnosed with diabetes after ﬁve
years. Altogether, ﬁve out of 27 women with HbA1c levels
≥39mmol/mol (≥5.7%) had not been diagnosed with diabetes
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after ﬁve years (2 NGT, 1 IFG, and 2 IGT). The correspond-
ing ﬁgure for women with 2-h capillary plasma glucose levels
≥12.2mmol/l (the diagnostic limit for diabetes outside of preg-
nancy) was eight out of 24 (1 NGT, 3 IFG, and 4 IGT).
HbA1c levels for the total study group were grouped
into quartiles. Median levels for HbA1c in mmol/mol [%]
in the respective quartiles were: 27 (range: 21–29) [4.6%
(range: 4.1–4.8%)] (n=56), 31 (30–31) [5.0% (4.9–5.0%)] (n=43), 33
(32–35) [5.2% (5.1–5.4%)] (n=51), and 40 (36–70) [5.8% (5.4–8.6%)]
(n=46). A logistic regression analysis, testing the predic-
tive value of HbA1c quartiles for the 5-year diabetes risk,
showed that women with HbA1c levels in quartile four had
a seven-fold increased risk of post-partum diabetes compared
to women with HbA1c levels in quartiles 1–3 (OR=7.0, 95%
CI: 3.3–14.6, p<0.0001). This association remained signiﬁcant
after adjustment for maternal age and the 2-h glucose level
during pregnancy (OR=5.5, 95% CI: 2.5–12.1, p<0.0001).
4. Discussion
The results of the present study conﬁrm our previous ﬁndings
that HbA1c levels in the upper quartile, measured close to the
diagnostic OGTT during pregnancy, predict diabetes develop-
ment during the ﬁve years after delivery [17]. To the best of
our knowledge, only four other studies have investigated an
association between HbA1c levels during pregnancy and the
risk of post-partum diabetes [18–21].
Using the WHO (1999) criteria for the diagnosis of GDM, Liu
et al. evaluated HbA1c, measured at 26–30 gestational weeks,
as a predictor of diabetes 1–5 years after delivery in 1263 Chi-
nese women [18]. Adjusting for various risk factors in a Cox
proportional hazards model, the hazard ratio for post-partum
diabetes was 2.11 (95% CI: 1.50–2.97) for every unit (%) increase
inHbA1c. Furthermore,when fasting glucose, 2-h glucose, and
HbA1c level during pregnancy were entered into the model
simultaneously, 2-h glucose and HbA1c level, but not fasting
glucose, remained signiﬁcant and positive predictors of post-
partum diabetes. In our previous study, both HbA1c and the
fasting glucose level during pregnancy were found to be inde-
pendent predictors of the 5-year diabetes risk [17]. A number
of risk factors for diabetes development after GDM have been
identiﬁed, which may in part differ from one population to
another [27]. The fact that the fasting glucose levels did not
predict diabetes in the study by Hsu et al. may be speciﬁc to
the Chinese population, as fasting plasma glucose has been
reported to be less sensitive for diagnosis of diabetes than the
2-h glucose level in the Asian population [28].
In a retrospective study from Korea, evaluating HbA1c at
26–30 gestational weeks as a diagnostic test for GDM, follow-
updata for at least 3months after pregnancywere available for
54 of 321women [19]. Based onROC-curve analysis, an optimal
cut-off value for HbA1c of 37mmol/mol (5.5%) could predict
diabeteswith 79% sensitivity and 73% speciﬁcity. However, the
restrictednumber ofwomen included in the analysismade the
results less reliable. Furthermore, long-term follow-up data
were not available. In another study from Warsaw, Poland,
Malinowska-Polubiec et al. evaluated various risk factors for
diabetes 0.5–10 years after pregnancy in 150womenwith ahis-
tory of GDM [20]. In that population both second-trimester and
third-trimester HbA1c were associated with increased relative
risks of post-partum diabetes. Finally, in a retrospective study
of 305 women in the Czech Republic, Bartakova et al. found
an optimal cut-off value from ROC-curve analysis (based on
Youden statistics) for mid-trimester HbA1c of 36mmol/mol
(5.4%) for any degree of post-partum glucose abnormality dur-
ing the ﬁrst year after pregnancy [21].
In addition to the 2-h plasma glucose concentration during
pregnancy, we have recently reported that (1) BMI at the ﬁrst
follow-up after pregnancy and (2) a non-European background
were the most important risk factors for development of dia-
betes ﬁve years after pregnancy in the total Mamma Study
cohort (deﬁningGDMby theWHO (1999) criteria) [29].However,
HbA1c was not included in the prediction model since it was
only measured in women diagnosed with GDM according to
clinical routine (EASD criteria). For this reason, we performed
a separate study restricted to these women.
At the time of the design of the Mamma Study, HbA1c was
not recommended as a diagnostic test for diabetes, nor as a
test early in pregnancy to rule out pre-existing diabetes. In
our material, an HbA1c level of ≥48mmol/mol (≥6.5%) dur-
ing the third trimester of pregnancy identiﬁed all women
with a diabetes diagnosis ﬁve years after pregnancy, some
of whom had been diagnosed with diabetes before the ﬁrst
follow-up and may have had pre-gestational diabetes. Fur-
thermore, an HbA1c level of ≥45mmol/mol (≥6.3%) identiﬁed
all but 1 woman with diabetes after ﬁve years, and an HbA1c
level ≥39mmol/mol (≥5.7%) identiﬁed all but 5 women with
a diabetes diagnosis during follow-up. On the other hand,
for the various thresholds, HbA1c had low sensitivity in
diagnosing diabetes using either NGT or NGT/IFT/IGT as a ref-
erence. These data provide evidence to suggest there may be
a useful HbA1c threshold above which all women should be
closely monitored, starting already during pregnancy, to pre-
vent diabetes development after delivery. Furthermore, after
adjustment for the 2-h glucose level, HbA1c levels equal to
and above the optimal cut-off level of the ROC curve were
associated with more than a 5-fold increased risk of post-
partum diabetes. This indicates that HbA1c analysis could be
an adjunct to the OGTT in identifying women who are at high
risk of developing post-partum diabetes.
A major limitation of the study was that HbA1c measure-
ments were only available for women with a clinical diagnosis
of GDM. Moreover, as previously reported [6], the overall par-
ticipation rate in the Mamma Study was less than 50%, which
may have introduced selection bias. As the diagnostic crite-
ria for GDM have changed worldwide since the time when
this study was initiated, the ﬁndings should be repeated and
validated in future studies using updated diagnostic crite-
ria [7–9]. Generalization to populations with different ethnic
backgrounds should also be done. The strengths of the study
were the uniform screening procedure in the region, based on
a universally applied OGTT, and the prospective study design
with long-term follow-up after pregnancy.
5. Conclusions
An HbA1c level of ≥36mmol/mol (≥5.4%), obtained close to
the twenty-eighth week of pregnancy, was associated with a
50 pr imary care d iabetes 1 1 ( 2 0 1 7 ) 46–51
more than 5-fold increased risk of diabetes ﬁve years after
pregnancy. A cut-off level for HbA1c of≥39mmol/mol (≥5.7%),
corresponding to the pre-diabetes range outside of pregnancy,
could reveal women with post-partum diabetes with high
speciﬁcity (97%) and high PPV (91%). Due to the low sensi-
tivity, HbA1c does not appear suitable as a screening test to
predict diabetes after GDM in all women, but it could be used
as a strategy for selecting high-risk women for lifestyle inter-
ventions to prevent diabetes, starting already in pregnancy.
The results should encourage further validation in large-scale
studies using new diagnostic criteria for GDM.
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